Jazz Pharmaceuticals has announced that it will acquire London-headquartered biopharma company GW Pharma for a total consideration of $7.2bn.
GW is focused on the discovery and development of therapeutics from its proprietary cannabinoid product platform.
The company’s lead product is Epidiolex (cannabidiol) oral solution, which is approved in patients aged one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC).